Evidence map›Paper›PMID 39251521›Full record

ArticleProbiotics and antimicrobial proteins2025

Oral Live-Carrier Vaccine of Recombinant Lactococcus lactis Inducing Prophylactic Protective Immunity Against Helicobacter pylori Infection.

Xiumei Ni, Yu Liu, Min Sun, Yajun Jiang, Yi Wang, Dingxin Ke, Gang Guo, Kaiyun Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Journal of microbiology and biotechnology · 2025
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Vaccines · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiumei NiBiopharmaceutical Research Institute, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610041, China.
Yu LiuBiopharmaceutical Research Institute, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610041, China.
Min SunBiopharmaceutical Research Institute, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610041, China.
Yajun JiangBiopharmaceutical Research Institute, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610041, China.
Yi WangBiopharmaceutical Research Institute, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610041, China.
Dingxin KeBiopharmaceutical Research Institute, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610041, China.
Gang GuoBiopharmaceutical Research Institute, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610041, China. guogang7001@163.com.
Kaiyun LiuBiopharmaceutical Research Institute, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610041, China. liukaiyun@wchscu.edu.cn.ORCID http://orcid.org/0009-0001-7460-5040

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori infects the gastric mucosa and induces chronic gastritis, peptic ulcers, and gastric cancer. Research has demonstrated that vaccination can induce a protective immune response and prevent H. pylori infection. Oral administration of the Lactococcus lactis live-carrier vaccine is safe and easily complied with by the public. In this study, two recombinant L. lactis strains were constructed that expressed antigens of H. pylori urease subunit alpha (UreA) and UreA fused with Escherichia coli heat-labile toxin B subunit (LTB-UreA), named LL-UreA and LL-LTB-UreA, respectively. The expression of antigen proteins was confirmed by Western blotting analysis. Survival assessment indicated that the engineered L. lactis could colonize in the digestive tract of BALB/c mice up to 10 days after the last oral administration with our immunization protocol. The ability to induce immune response and immune protective efficacy of the L. lactis were confirmed. These results indicated that oral administration with LL-UreA or LL-LTB-UreA could induce UreA-specific mucosal secretory IgA (sIgA) and cellular immune response, significantly increasing the cytokines levels of interferon-gamma (IFN-γ), interleukin (IL)-17A, and IL-10, together with the proportion of CD4

Indexed as

Bacterial VaccinesHelicobacter InfectionsHelicobacter pyloriLactococcus lactisAdministration, OralAnimalsBacterial ProteinsBacterial ToxinsCytokinesEnterotoxinsEscherichia coli ProteinsFemaleMiceMice, Inbred BALB CUreaseBacterial ProteinsBacterial ToxinsBacterial VaccinesCytokinesEnterotoxinsEscherichia coli Proteinsheat-labile enterotoxin, E coliUreaseHelicobacter pyloriImmune responsesLactococcus lactisOral deliveryVaccine

Identifiers

PMID39251521

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.